Cargando…

Comparison of the Therapeutic Efficacies of Topical Rivoceranib and Topical Bevacizumab in a Murine Model of Corneal Neovascularization

Background and Objectives: Corneal neovasculariziation (CNV) is a serious vision-threatening complication; however, all therapeutics have their clinical limitations. The aim of this study is to investigate the efficacy of topical rivoceranib compared with topical bevacizumab in a murine model of cor...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Hyeon Jeong, Woo, Je Moon, Ji, Yong Sok, Yoon, Kyung Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6915418/
https://www.ncbi.nlm.nih.gov/pubmed/31703332
http://dx.doi.org/10.3390/medicina55110729
_version_ 1783480011391500288
author Yoon, Hyeon Jeong
Woo, Je Moon
Ji, Yong Sok
Yoon, Kyung Chul
author_facet Yoon, Hyeon Jeong
Woo, Je Moon
Ji, Yong Sok
Yoon, Kyung Chul
author_sort Yoon, Hyeon Jeong
collection PubMed
description Background and Objectives: Corneal neovasculariziation (CNV) is a serious vision-threatening complication; however, all therapeutics have their clinical limitations. The aim of this study is to investigate the efficacy of topical rivoceranib compared with topical bevacizumab in a murine model of corneal neovascularization (CNV). Materials and Methods: Murine CNV was induced by means of total de-epithelization and alkali burn. Mice were divided into five groups according to topical treatment: untreated control, phosphate-buffered saline (PBS), 0.1% and 0.5% rivoceranib, and 0.5% bevacizumab. CNV area and index were measured 7 and 14 days after treatment. After corneal tissues were excised at day 14, the blood and lymphatic vessels were quantified by cluster of differentiation 31 (CD31) and lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1) immunofluorescence, respectively. Results: After 14 days, treatment groups with 0.1% and 0.5% rivoceranib and 0.5% bevacizumab showed a decrease in CNV area and index compared with the untreated and PBS groups (all p < 0.01). Blood and lymphatic vascularization significantly decreased in the 0.5% rivoceranib and 0.5% bevacizumab groups, as measured by CD31 and LYVE1 immunofluorescence. There was no significant difference of vascularization between the 0.5% rivoceranib and bevacizumab groups. Conclusions: Topical application of rivoceranib could effectively decrease CNV equivalent to topical bevacizumab in a murine model.
format Online
Article
Text
id pubmed-6915418
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69154182019-12-24 Comparison of the Therapeutic Efficacies of Topical Rivoceranib and Topical Bevacizumab in a Murine Model of Corneal Neovascularization Yoon, Hyeon Jeong Woo, Je Moon Ji, Yong Sok Yoon, Kyung Chul Medicina (Kaunas) Article Background and Objectives: Corneal neovasculariziation (CNV) is a serious vision-threatening complication; however, all therapeutics have their clinical limitations. The aim of this study is to investigate the efficacy of topical rivoceranib compared with topical bevacizumab in a murine model of corneal neovascularization (CNV). Materials and Methods: Murine CNV was induced by means of total de-epithelization and alkali burn. Mice were divided into five groups according to topical treatment: untreated control, phosphate-buffered saline (PBS), 0.1% and 0.5% rivoceranib, and 0.5% bevacizumab. CNV area and index were measured 7 and 14 days after treatment. After corneal tissues were excised at day 14, the blood and lymphatic vessels were quantified by cluster of differentiation 31 (CD31) and lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1) immunofluorescence, respectively. Results: After 14 days, treatment groups with 0.1% and 0.5% rivoceranib and 0.5% bevacizumab showed a decrease in CNV area and index compared with the untreated and PBS groups (all p < 0.01). Blood and lymphatic vascularization significantly decreased in the 0.5% rivoceranib and 0.5% bevacizumab groups, as measured by CD31 and LYVE1 immunofluorescence. There was no significant difference of vascularization between the 0.5% rivoceranib and bevacizumab groups. Conclusions: Topical application of rivoceranib could effectively decrease CNV equivalent to topical bevacizumab in a murine model. MDPI 2019-11-07 /pmc/articles/PMC6915418/ /pubmed/31703332 http://dx.doi.org/10.3390/medicina55110729 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yoon, Hyeon Jeong
Woo, Je Moon
Ji, Yong Sok
Yoon, Kyung Chul
Comparison of the Therapeutic Efficacies of Topical Rivoceranib and Topical Bevacizumab in a Murine Model of Corneal Neovascularization
title Comparison of the Therapeutic Efficacies of Topical Rivoceranib and Topical Bevacizumab in a Murine Model of Corneal Neovascularization
title_full Comparison of the Therapeutic Efficacies of Topical Rivoceranib and Topical Bevacizumab in a Murine Model of Corneal Neovascularization
title_fullStr Comparison of the Therapeutic Efficacies of Topical Rivoceranib and Topical Bevacizumab in a Murine Model of Corneal Neovascularization
title_full_unstemmed Comparison of the Therapeutic Efficacies of Topical Rivoceranib and Topical Bevacizumab in a Murine Model of Corneal Neovascularization
title_short Comparison of the Therapeutic Efficacies of Topical Rivoceranib and Topical Bevacizumab in a Murine Model of Corneal Neovascularization
title_sort comparison of the therapeutic efficacies of topical rivoceranib and topical bevacizumab in a murine model of corneal neovascularization
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6915418/
https://www.ncbi.nlm.nih.gov/pubmed/31703332
http://dx.doi.org/10.3390/medicina55110729
work_keys_str_mv AT yoonhyeonjeong comparisonofthetherapeuticefficaciesoftopicalrivoceranibandtopicalbevacizumabinamurinemodelofcornealneovascularization
AT woojemoon comparisonofthetherapeuticefficaciesoftopicalrivoceranibandtopicalbevacizumabinamurinemodelofcornealneovascularization
AT jiyongsok comparisonofthetherapeuticefficaciesoftopicalrivoceranibandtopicalbevacizumabinamurinemodelofcornealneovascularization
AT yoonkyungchul comparisonofthetherapeuticefficaciesoftopicalrivoceranibandtopicalbevacizumabinamurinemodelofcornealneovascularization